3 results match your criteria: "The Christie National Health Service Foundation Trust and University of Manchester[Affiliation]"
Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019.
Cancer
April 2024
Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Article Synopsis
- Anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is complex due to the balance between stroke risk and bleeding, with significant variations in prescribing practices observed.
- A study analyzed 177,065 AF patients and found that 11.7% had cancer, and those patients were less likely to receive oral anticoagulants (OAC), especially those with hematological and lung cancers.
- The results indicate that elderly patients (≥85 years) had the lowest rates of OAC prescribing, highlighting a need for more research on the benefits of anticoagulation in this demographic and specific cancer types.
Progression-free survival in the ICON8 trial - Authors' reply.
Lancet
September 2020
Department of Medical Oncology, The Christie National Health Service Foundation Trust and University of Manchester, Manchester, UK.
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.
Methods: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries.